Impact BioMedical Inc. IBO

Full chart Compare
Set alert

Price alert · IBO

All alert types
4.05 USD -0.05 (-1.22%)

Nov 5, 2026, 2:10 PM EST

4.00 Day range 4.48
2.43 52-week range 10.51
YTD
-36.62%
1 year
-39.82%
Market cap
34.99M
EPS (ttm)
11.11
Shares out
11.50M
P/E ratio
0.36
YTD return
-36.62%
1-year return
-39.82%
Volume
7.68K
Avg volume
16.77K
Open
4.10
Previous close
4.10
Day's range
4.00 – 4.48
52-week range
2.43 – 10.51

5D +0.16 (+4.15%)

3.7544.254.50FriMonTueWedThu4.02

Key statistics

Enterprise value
21.75M
PEG ratio
0.00
Price / sales
0.00
Price / book
0.53
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-1.33M
Total cash
2.67M
Total debt
8.01M
Return on equity
3.45%
Short % of float
0.00%
50-day average
2.23
200-day average
2.17

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
IBO Revenue — quarterly 3.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IBO Net income — quarterly -699.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
IBO EPS — quarterly -0.01
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

About Impact BioMedical Inc.

Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on IBO — it syncs with the Stock Master app.

Institution ownership

IBO institution ownership
Holder% heldSharesValueReported
Ferguson Wellman Capital Management, Inc.0.00%36,36452.36KSep 29, 2024
HRT Financial LP0.00%12,50218.00KSep 29, 2024
Wells Fargo & Company0.00%2941Sep 29, 2024
Jane Street Group, LLC0.00%13,36119.24KSep 29, 2024
Bank of America Corporation0.00%2,5963.74KSep 29, 2024
Barclays Plc0.00%1,1201.61KSep 29, 2024

Fund ownership

IBO fund ownership
Holder% heldSharesValueReported
Vanguard Balanced Index Fund0.00%154,000221.76KSep 29, 2024
Vanguard Total Stock Market Index Fund0.00%5,171,0527.45MSep 29, 2024
Fidelity Extended Market Index Fund0.00%26,77038.55KOct 30, 2024
Fidelity Series Total Market Index Fund0.00%5,8208.38KOct 30, 2024
Fidelity Total Market Index Fund0.00%2,4493.53KOct 30, 2024